New drugs for children and adolescents with cancer: the need for novel development pathways

Gilles Vassal, C. Michel Zwaan, David M. Ashley, +4

The Lancet Oncology

Novel Development PathwaysOncologyMedicinePediatricsNew Drugs +8

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer

Gilles Vassal, Raphaël F. Rousseau, P. Blanc, +10

European Journal of Cancer

Cancer ManagementCancer EducationGynecology OncologyTreatment DevelopmentPre-clinical Pharmacology +22

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

Nathalie Gaspar, Lynley V. Marshall, Debbie Binner, +25

Annals of Oncology

Predicting early mortality among elderly patients hospitalised in medical wards via emergency department: The SAFES cohort study

Moustapha Dramé, Nicolas Jovenin, Jean‐Luc Novella, +9

The journal of nutrition health & aging

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

Andrew D.J. Pearson, Claudia Rössig, Giovanni Lesa, +42

European Journal of Cancer

The geriatric patient: Use of acute geriatrics units in the emergency care of elderly patients in France

Dominique Somme, C. Lazarovici, Moustapha Dramé, +10

Archives of Gerontology and Geriatrics

NursingElderly PatientsGeriatricsPatient SafetyElderly Care +7

10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers

Andrew D.J. Pearson, Delphine Heenen, Pamela Kearns, +4

The Lancet Oncology

MedicineChild HealthPediatricsGynecologyPaediatric Medicine +10

Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer

Gilles Vassal, Pamela Kearns, P. Blanc, +3

European Journal of Cancer

Family MedicineSubstance UseDrug PolicyAdolescent Behavioral HealthEducation +16

Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

Claudia Rössig, Andrew D.J. Pearson, Gilles Vassal, +12

Journal of Clinical Oncology

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

Lucia Taramasso, P Lorenzini, Antonio Di Biagio, +195

Journal of Antimicrobial Chemotherapy